{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464380525
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[cytomegalovirus]] glycoprotein&nbsp;B
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 153101-26-9
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG = D09852
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Regavirumab''' is a [[human]] [[monoclonal antibody]] against infections with [[cytomegalovirus]].<ref>{{cite journal|pmid=7945531|year=1994|last1=Arizono|first1=H|last2=Sugano|last3=Kaida|last4=Shibusawa|last5=Karasawa|last6=Esumi|last7=Kondo|last8=Kiyoki|title=Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys|volume=44|issue=7|pages=909â€“13|journal=Arzneimittel-Forschung|first2=T|first3=S|first4=K|first5=Y|first6=Y|first7=S|first8=M}}</ref>

==References==
{{reflist}}

{{Monoclonals for infectious disease and toxins}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{antiinfective-drug-stub}}
{{monoclonal-antibody-stub}}